Efficacy, Safety, and Immunogenicity of AVT02 With Moderate-to-Severe Chronic Plaque Psoriasis

NCT03849404 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
413
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Alvotech Swiss AG